2LUZ | pdb_00002luz

Solution NMR Structure of CalU16 from Micromonospora echinospora, Northeast Structural Genomics Consortium (NESG) Target MiR12

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	0.9 mM [U-100% 13C; U-100% 15N] mir12.006, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	90% H2O/10% D2O		6.5	ambient	298
2	2D 1H-13C HSQC	0.9 mM [U-100% 13C; U-100% 15N] mir12.006, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	90% H2O/10% D2O		6.5	ambient	298
3	3D HNCO	0.9 mM [U-100% 13C; U-100% 15N] mir12.006, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	90% H2O/10% D2O		6.5	ambient	298
4	3D CBCA(CO)NH	0.9 mM [U-100% 13C; U-100% 15N] mir12.006, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	90% H2O/10% D2O		6.5	ambient	298
5	3D HNCACB	0.9 mM [U-100% 13C; U-100% 15N] mir12.006, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	90% H2O/10% D2O		6.5	ambient	298
6	3D 1H-13C NOESY aliphatic	0.9 mM [U-100% 13C; U-100% 15N] mir12.006, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	90% H2O/10% D2O		6.5	ambient	298
7	3D 1H-13C NOESY aromatic	0.9 mM [U-100% 13C; U-100% 15N] mir12.006, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	90% H2O/10% D2O		6.5	ambient	298
8	3D HCCH-TOCSY	0.9 mM [U-100% 13C; U-100% 15N] mir12.006, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	90% H2O/10% D2O		6.5	ambient	298
9	3D HCCH-TOCSY	0.9 mM [U-100% 13C; U-100% 15N] mir12.006, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 100 % D2O, 50 uM DSS	100% D2O		6.5	ambient	298
10	2D 1H-13C HSQC	0.9 mM [U-100% 15N], 5% 13C stereo mir12.008, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	90% H2O/10% D2O		6.5	ambient	298
11	4D CC-NOESY	0.9 mM [U-100% 13C; U-100% 15N] mir12.006, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 100 % D2O, 50 uM DSS	100% D2O		6.5	ambient	298
12	3D HBHA(CO)NH	0.9 mM [U-100% 13C; U-100% 15N] mir12.006, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	90% H2O/10% D2O		6.5	ambient	298
13	3D HCCH-COSY	0.9 mM [U-100% 13C; U-100% 15N] mir12.006, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	90% H2O/10% D2O		6.5	ambient	298
14	3D C(CO)NH	0.9 mM [U-100% 13C; U-100% 15N] mir12.006, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	90% H2O/10% D2O		6.5	ambient	298
15	3D H(CCO)NH	0.9 mM [U-100% 13C; U-100% 15N] mir12.006, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	90% H2O/10% D2O		6.5	ambient	298
16	NUS 3D 1H-13C NOESY aliphatic	0.9 mM [U-100% 13C; U-100% 15N] mir12.011, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	90% H2O/10% D2O		6.5	ambient	298
17	NUS 3D 1H-15N NOESY	0.9 mM [U-100% 13C; U-100% 15N] mir12.011, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	90% H2O/10% D2O		6.5	ambient	298
18	3D 1H-15N NOESY	0.9 mM [U-100% 13C; U-100% 15N] mir12.006, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 100 mM NaCL, 1 x Proteinase Inhibitors, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	90% H2O/10% D2O		6.5	ambient	298

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE	800
2	Varian	INOVA	600
3	Bruker	AVANCE III	600

NMR Refinement
Method	Details	Software
simulated annealing	CNS WATER REFINEMENT	CNS

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	100
Conformers Submitted Total Number	20
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	refinement	CNS	1.3	Brunger, Adams, Clore, Gros, Nilges and Read
2	structure solution	CNS	1.3	Brunger, Adams, Clore, Gros, Nilges and Read
3	geometry optimization	CNS	1.3	Brunger, Adams, Clore, Gros, Nilges and Read
4	refinement	CYANA	3.0	Guntert, Mumenthaler and Wuthrich
5	geometry optimization	CYANA	3.0	Guntert, Mumenthaler and Wuthrich
6	structure solution	CYANA	3.0	Guntert, Mumenthaler and Wuthrich
7	data analysis	AutoStructure	ASDP-1.0	Huang, Tejero, Powers and Montelione
8	refinement	AutoStructure	ASDP-1.0	Huang, Tejero, Powers and Montelione
9	processing	NMRPipe	2008 linux9	Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
10	collection	TopSpin	2.1.4 and 3.1	Bruker Biospin
11	collection	VnmrJ	1.1 D	Varian
12	chemical shift assignment	PINE		Bahrami, Markley, Assadi, and Eghbalnia
13	data analysis	Sparky	3.113	Goddard
14	geometry optimization	TALOS+		Shen, Cornilescu, Delaglio and Bax
15	geometry optimization	PALES		PALES (Zweckstetter, Bax)
16	structure validation	PSVS	1.5	Bhattacharya, Montelione
17	refinement	FMCGUI		Alex Lemak, Cheryl Arrowsmith, University of Toronto

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.